Please use this identifier to cite or link to this item:
|Title:||Development of a water-soluble dextrin-amphotericin B conjugate for the treatment of Leishmaniasis|
Tomás, A. M.
Gama, F. M.
|Citation:||Fidalgo, João; Silva-Carvalho, Ricardo; Leal, S.; Cruz, T.; Tomás, A. M.; Parpot, Pier; Gama, F. M., Development of a water-soluble dextrin-amphotericin B conjugate for the treatment of Leishmaniasis. CHEMPOR 2018 - 13th International Chemical and Biological Engineering Conference (Book of Extended Abstracts). No. P-BB17, Aveiro, Portugal, Oct 2-4, 236-237, 2018.|
|Abstract(s):||Leishmaniasis is a life-threatening disease with a worldwide distribution and a huge impact especially in immunocompromised patients. Nowadays, the use of amphotericin B, an antifungal agent, or other marketed strategies to overcome this disease exhibit major clinical limitations. Thus, other strategies have been pursued to achieve better clinical treatments and decrease toxicity. In this work, a promising conjugate based on dextrin and amphotericin B was developed. An HPLC-MS detection method was also developed in order to determine the amphotericin B concentration and the encapsulation efficiency. This water-soluble polymer-drug conjugate has shown promising effects against axenic cultures of Leishmania amazonensis parasite and infected macrophages, without being cytotoxic to the latter.|
|Appears in Collections:|
CDQuim - Comunicações e Proceedings